CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Older adults aged ≥80 with HR+/HER2− metastatic breast cancer (MBC) are often underrepresented in clinical trials, leaving clinicians with limited data to guide treatment decisions. Given the increasing prevalence of this age group, real-world evidence is crucial to inform therapeutic strategies. Methods: We performed a multicenter retrospective study across seven Italian oncology units, focusing on patients aged 80 or above who received CDK4/6 inhibitors in combination with endocrine therapy between January 2020 and May 2024. Baseline characteristics, treatment details, and adverse events were recorded. Primary endpoints were progression-free survival (PFS) and overall survival (OS); toxicity was assessed using CTCAE v5.0. Follow-up was estimated using the reverse Kaplan–Meier method. Results: Eighty patients were included, with a median age of 83. Over half had visceral metastases, and 41.0% were frail (G8 ≤ 14). Approximately 44.0% of patients started treatment at a reduced dose. The median PFS was 13 months (95.0% CI 9.3–18.0), and the median OS was 15 months (95.0% CI 11.8–18.2). Hematologic toxicity was frequent, with neutropenia occurring in 58.8% (25.0% grade ≥ 3) and anemia in 12.5% (2.5% grade ≥ 3). Asthenia was reported in 16.2% (5.0% grade ≥ 3). Diarrhea occurred in 3.8% overall, mainly in patients treated with abemaciclib (42.9% any grade; 14.3% grade ≥ 3). ALT/AST elevations were observed in 8.8% (1.2% grade ≥ 3), and QTc prolongation in 2.5% (1.2% grade ≥ 3, all with ribociclib). Grade ≥ 3 events were uncommon and generally manageable. Conclusions: CDK4/6 inhibitor-based therapy is feasible in patients aged ≥80 years, with outcomes and tolerability comparable to those observed in younger elderly. Our results highlight the importance of individualized treatment strategies in this oldest-old population.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study
- Date Crossref
- 13/10/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Foggia Department of Medical and Surgical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Istituto Tumori Bari pays non établi dans la noticeÉtablissement de santé
-
Ospedale San Paolo pays non établi dans la noticeÉtablissement de santé
-
“Dario Camberlingo” Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
"Dario Camberlingo" Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
“Teresa Masselli Mascia” Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
"Teresa Masselli Mascia" Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
Oncology Unit pays non établi dans la noticeInstitution
-
“Sacro Cuore di Gesù” Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
“Mons. A. R. Dimiccoli” Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
"Mons. A. R. Dimiccoli" Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
“San Paolo” Hospital Oncology Unit pays non établi dans la noticeÉtablissement de santé
Department of Medical and Surgical Sciences — University of Foggia, Istituto Tumori Bari et Ospedale San Paolo, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.